FREMONT, Calif., March 13, 2015 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused
on cardio-renal, gastrointestinal, and metabolic diseases, today
announced that Mike Raab, President
and Chief Executive Officer, will present a corporate overview at
the 22nd Annual Future Leaders in the Biotech Industry Conference
on Friday, March 20, 2015, at
9:30 a.m. Eastern Time. The
conference will be held at the Millennium Broadway Hotel &
Conference Center in New York.
The presentation will be available through a live audio webcast
accessible through a link in the Investor Relations section of
Ardelyx's website at ir.ardelyx.com. A replay of the webcast will
be available at this site for 30 days.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
minimally-systemic, small molecule therapeutics that work
exclusively in the gastrointestinal tract to treat cardio-renal,
gastrointestinal and metabolic diseases. Ardelyx has developed a
proprietary drug discovery and design platform enabling it, in a
rapid and cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, the Company has discovered and
designed tenapanor. Ardelyx formed a partnership with AstraZeneca
in October 2012 to develop and
commercialize tenapanor. The Company and AstraZeneca have
completed two Phase 2b clinical trials evaluating tenapanor to
treat patients with constipation-predominant irritable bowel
syndrome (IBS-C), and to treat hyperphosphatemic patients with
chronic kidney disease on dialysis (CKD-5D). In an
ongoing Phase 2a clinical study in CKD patients, tenapanor is being
evaluated for its effect on kidney function and fluid overload. In
addition to tenapanor, the Company has discovered small molecule
NaP2b inhibitors for the treatment of hyperphosphatemia in CKD-5D,
a program licensed to Sanofi, and independently is advancing
several additional research programs focused in cardio-renal,
gastrointestinal and metabolic diseases. Ardelyx is located in
Fremont, California. For more
information, please visit Ardelyx's website at www.ardelyx.com.
Logo - http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-22nd-annual-future-leaders-in-the-biotech-industry-conference-300050128.html
SOURCE Ardelyx, Inc.